Fluorofenidone
Based on 1 publication(s) in Google Scholar
Fluorofenidone (AKF-PD) is an orally active compound with anti-fibrotic, antioxidant, and anti-inflammatory pharmacological effects. Fluorofenidone downregulates the expression of ACSL4, upregulates GPX4 expression and inhibits the NF-κB signaling pathway to alleviate inflammation and fibrosis. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Fluorofenidone demonstrates protective effects against chronic lung injury in mice. Fluorofenidone can be used for the study of chronic obstructive pulmonary disease (COPD), pulmonary interstitial fibrosis (PIF) and non-small cell lung cancer (NSCLC).
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.78%
- CAS No.: 848353-85-5
- 화학식: C12H10FNO
- 분자량:203.21
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Pyroptosis Compound Library
HY-L059
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Osteogenesis Compound Library
HY-L131
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Fluorofenidone
More
Biological Activity
|
ACSL4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NIH3T3 | IC50 |
2.75 mM
Compound: AKF-PD
|
Anti-fibrosis activity in mouse NIH/3T3 cells assessed as inhibition of proliferation after 72 hrs by MTT assay
Anti-fibrosis activity in mouse NIH/3T3 cells assessed as inhibition of proliferation after 72 hrs by MTT assay
|
[PMID: 22342629] |
| NIH3T3 | IC50 |
4.2 mM
Compound: Fluorofenidone
|
Antiproliferative activity against mouse NIH/3T3 cells by MTT assay
Antiproliferative activity against mouse NIH/3T3 cells by MTT assay
|
[PMID: 28122457] |
Fluorofenidone (24 h) partially reverses the inhibition of cell viability and reduces the levels of inflammatory factors IL-1β, IL-6, and TNF-α in the culture supernatant induced by cigarette smoke extract (CSE) in BEAS-2B cells[1].
Fluorofenidone (24 h) partially reverses the increase in MDA level and decrease in GSH level in BEAS-2B cell supernatant caused by CSE[1].
Fluorofenidone (24 h) improves CSE-induced mitochondrial damage, downregulates the expression of ACSL4 and upregulates the expression of GPX4 in BEAS-2B cells[1].
Fluorofenidone (200-800 μg/mL, 24 h) inhibits proliferation of A549 and H1299 cells in a dose-dependent manner, with EC50 of 1030 μg/mL (A549) and 1118 μg/mL (H1299)[3].
Fluorofenidone (400-800 μg/mL, 3 h) significantly reduces the percentage of EdU-positive proliferating cells[3].
Fluorofenidone (200-800 μg/mL, 12-24 h) dose- and time-dependently inhibits cell migration and reduces the number of invasive cells in A549 and H1299 cells[3].
Fluorofenidone (200-800 μg/mL) upregulates the expression of epithelial marker E-cadherin and downregulates mesenchymal markers MMP9, vimentin, and SNAIL in A549 and H1299 cells[3].
Fluorofenidone (200-800 μg/mL) suppresses phosphorylation of JNK, ERK, P38 (MAPK pathway) and p-PI3K, p-AKT, p-mTOR (PI3K/AKT/mTOR pathway) in A549 and H1299 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fluorofenidone (0.45% in diet, p.o., 14 days) markedly alleviates hepatic inflammation in 3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC)-induced cholestasis model of mice[2].
Fluorofenidone (400 mg/kg, p.o., daily, 3 weeks) combined with Cisplatin (HY-17394) significantly reduces the size, weight and volume of subcutaneous tumors in C57 mice bearing Lewis lung cancer cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J mice (4-week-old, 18-20 g) were used to construct the chronic obstructive pulmonary disease (COPD) model[1]
-
Dosage:5 mg/kg
-
Administration:i.p., once daily, 7 weeks
-
Result:Alleviated CS/LPS-induced lung tissue morphological damage, including reducing interstitial inflammatory cell infiltration, alleviating lung overexpansion, thinning alveolar septa, and lowering lung injury score.
Reduced the levels of inflammatory factors IL-1β, IL-6, and TNF-α in bronchoalveolar lavage fluid (BALF) and serum.
Inhibited lung collagen deposition, decreased lung fibrosis score, downregulated mRNA and protein expressions of fibrosis markers α-SMA, FAP, and COL3A1 in lung tissue, and reduced lung hydroxyproline content.
Downregulated ACSL4 expression and upregulated GPX4 expression in lung tissue, reversed CS/LPS-induced increase in MDA level and decrease in GSH level in lung tissue and serum.
-
Animal Model:3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC)-induced cholestasis model of 7-week-old male C57BL/6J mice[2]
-
Dosage:0.45% in diet
-
Administration:p.o., 14 days
-
Result:Reduced serum ALT, AST, ALP, and TBA levels, as well as hepatic BAs levels, and decreased the liver/body weight ratio.
Reduced mRNA levels of hepatic inflammatory cytokines and chemokines, lowered serum levels of these inflammatory factors, and decreased F4/80 expression to reduce macrophage infiltration.
Downregulated mRNA levels of profibrogenic markers, inhibited phosphorylation of Smad2/3, and reduced α-SMA protein level, thus mitigating hepatic fibrosis.
Downregulated expression of Cyp7a1 and Cyp27a1, upregulated expression of hepatic detoxification enzymes, and facilitated nuclear translocation.
Suppressed phosphorylation of Erk1/2, reduced Egr-1 protein level, and blocked the Tgfβ1/Smad pathway.
-
Animal Model:C57 mice (5-week-old, 16-18 g) were used to construct the Lewis lung cancer subcutaneous xenograft model by subcutaneously injecting 5 × 105 Lewis lung cancer cells (C7205) into the axillary region[3]
-
Dosage:400 mg/kg combined with Cisplatin (5 mg/kg, i.p., weekly, 3 weeks)
-
Administration:p.o., daily, 3 weeks
-
Result:Reduced the size, weight and volume of subcutaneous tumors.
Downregulated the expression of mesenchymal marker N-cadherin.
Chemical Information
-
CAS No. 848353-85-5
-
Appearance Solid
-
분자량 203.21
-
화학식 C12H10FNO
-
Color White to off-white
-
SMILES
O=C1C=CC(C)=CN1C2=CC=CC(F)=C2
-
Synonyms
AKF-PD
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Fluorofenidone alleviates cigarette smoke exposure-induced chronic lung injury by targeting ferroptosis. [Abstract]2024 Dec 30;14(1):32149. PMID: 39738585
용액&용해도
DMSO : 140 mg/mL (688.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.33 mg/mL (11.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (23.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.33 mg/mL (11.47 mM); Clear solution
This protocol yields a clear solution of ≥ 2.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (23.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wu Y, et al. Fluorofenidone alleviates cigarette smoke exposure-induced chronic lung injury by targeting ferroptosis. Sci Rep. 2024 Dec 30;14(1):32149. [Content Brief]
[2]. Wang H,et al. Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice. Biochim Biophys Acta Mol Basis Dis. 2022 Dec 1;1868(12):166556. [Content Brief]
[3]. Wang S, et al. Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression. Transl Lung Cancer Res. 2024 Nov 30;13(11):3175-3188. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.9210 mL | 24.6051 mL | 49.2102 mL | 123.0254 mL |
| 5 mM | 0.9842 mL | 4.9210 mL | 9.8420 mL | 24.6051 mL | |
| 10 mM | 0.4921 mL | 2.4605 mL | 4.9210 mL | 12.3025 mL | |
| 15 mM | 0.3281 mL | 1.6403 mL | 3.2807 mL | 8.2017 mL | |
| 20 mM | 0.2461 mL | 1.2303 mL | 2.4605 mL | 6.1513 mL | |
| 25 mM | 0.1968 mL | 0.9842 mL | 1.9684 mL | 4.9210 mL | |
| 30 mM | 0.1640 mL | 0.8202 mL | 1.6403 mL | 4.1008 mL | |
| 40 mM | 0.1230 mL | 0.6151 mL | 1.2303 mL | 3.0756 mL | |
| 50 mM | 0.0984 mL | 0.4921 mL | 0.9842 mL | 2.4605 mL | |
| 60 mM | 0.0820 mL | 0.4101 mL | 0.8202 mL | 2.0504 mL | |
| 80 mM | 0.0615 mL | 0.3076 mL | 0.6151 mL | 1.5378 mL | |
| 100 mM | 0.0492 mL | 0.2461 mL | 0.4921 mL | 1.2303 mL |
Fluorofenidone Related Classifications
HY-121246 Related Classifications
Powered by Bioz